Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA; Mental Illness Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, 94304, USA
Auto-generated profile, based on publicly available information
Divya Rajasekharan
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA; Mental Illness Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, 94304, USA
Clinical transcranial magnetic stimulation (TMS) for depression routinely relies on the scalp-based BeamF3 targeting method to identify stimulation targets in the dorsolateral prefrontal cortex (dLPFC). Scalp-based targeting offers a low-cost and easily implemented method for TMS coil placement, enhancing treatment availability. However, limited anatomical and functional specificity of the BeamF3 method may affect treatment outcomes, motivating assessment of the clinical standard. In a naturalistic clinical trial of TMS conduced at four Veterans Affairs hospitals, the authors evaluate the BeamF3 method using neuroimaging incorporated before TMS, after five treatment sessions, and after all thirty sessions. Personalized anatomical and electric field (E-field) models were developed to assess target location and network engagement, as well as subsequent effects on clinical outcomes. Anatomical models demonstrate that the BeamF3 method produced reliable targets in the dLPFC across individuals and repeated treatment sessions. E-field models revealed that baseline anticorrelation between the stimulation center and the sgACC was associated with antidepressant symptom response after five TMS sessions () and at the end of treatment (). Relatedly, E-field magnitude at the sgACC-anticorrelated peak in the prefrontal cortex correlated with symptom response throughout treatment (early treatment: ; end of treatment: ). This work establishes that scalp-based targeting can produce reliable targets in the dLPFC and be successfully evaluated using a combination of neuroimaging and E-field modeling in pragmatic, multisite applications. Importantly, this investigation also found that significant network effects occur early in treatment and that BeamF3 targets can engage functional mechanisms in TMS.